Diversify Advisory Services LLC Cuts Position in AstraZeneca PLC (NASDAQ:AZN)

Diversify Advisory Services LLC lessened its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 23.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 12,088 shares of the company’s stock after selling 3,681 shares during the quarter. Diversify Advisory Services LLC’s holdings in AstraZeneca were worth $810,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the business. Diversify Wealth Management LLC lifted its stake in shares of AstraZeneca by 3.6% during the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock worth $295,000 after purchasing an additional 153 shares in the last quarter. Clarius Group LLC lifted its position in AstraZeneca by 3.3% during the 4th quarter. Clarius Group LLC now owns 10,542 shares of the company’s stock worth $691,000 after acquiring an additional 334 shares in the last quarter. Oak Ridge Investments LLC boosted its holdings in AstraZeneca by 5.4% in the 4th quarter. Oak Ridge Investments LLC now owns 143,973 shares of the company’s stock worth $9,433,000 after acquiring an additional 7,341 shares during the period. Aaron Wealth Advisors LLC grew its position in AstraZeneca by 8.3% in the fourth quarter. Aaron Wealth Advisors LLC now owns 18,842 shares of the company’s stock valued at $1,235,000 after acquiring an additional 1,440 shares in the last quarter. Finally, Veery Capital LLC raised its stake in shares of AstraZeneca by 4.7% during the fourth quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock valued at $230,000 after purchasing an additional 157 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Price Performance

Shares of AZN opened at $67.96 on Wednesday. The firm has a market cap of $210.75 billion, a price-to-earnings ratio of 32.52, a PEG ratio of 1.04 and a beta of 0.46. The stock has a 50 day moving average of $66.14 and a 200-day moving average of $74.39. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.87 EPS. As a group, analysts forecast that AstraZeneca PLC will post 4.11 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.